Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Turkey’s former minister of health explains how he is working to pass on his experience and knowledge to the next generation of health policy makers around the world, and discusses the…
The president of Turkey’s social security institution, the SGK, discusses the evolution of healthcare spending over the past three years, and the underpinning principles guiding their drug reimbursement policy decisions.…
In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East. An…
Within the Ministry’s wide scope of activities aimed at promoting Turkish various industries and trade, what special role does the pharmaceutical sector play within these aspirations? The world we live…
Focus Reports has been here a bit more than three months, and heard different opinions. Some said highlighted Turkey’s strategic advantages – population, age distribution, geography, political and economic stability…
Would you like to provide our international readers with a brief introduction into Novo Nordisk’s Turkish affiliate? As you may know, Novo Nordisk has a rich history of over 85…
You are managing partner of Egon Zehnder Turkey since 2007. Could you start by introducing the company to our readers and its scope of activities in Turkey? Egon Zehnder International…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
Cegedim has become a very strong partner for pharmaceutical companies worldwide, including Turkey. Nevertheless, with respect to healthcare, there are probably as many systems as countries. How does Cegedim adapt…
Pharmaceutical Executive and Focus Reports are of course about the industry but also about the people making it happen. So before anything would you like to introduce yourself to our…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
In an environment where the line between generic and innovator companies is less and less relevant, due to the growing trend of innovators integrating generics products in their portfolio through…
See our Cookie Privacy Policy Here
